Pharmaceutical firm Jubilant Organosys today reported 50.14 per cent decline in consolidated net profit at Rs 62.73 crore for the quarter ended June 30, as compared with the same period a year ago.
The company had posted a net profit of Rs 125.82 crore in the first quarter last fiscal.
Net sales during the quarter stood at Rs 981.51 crore as against Rs 896.36 crore in the comparable period last fiscal, up 9.49 per cent, Jubilant Organosys said in a statement.
During the quarter, the company incurred a loss of Rs 20.8 crore, which included a loss of Rs 3.8 crore on mark to market on interest rates swap and amortisation of unrealised loss Rs 17 crore on restatement of foreign currency loans, it added.
Sales from pharma and life sciences products and services division grew by 4.3 per cent to Rs 813 crore during the quarter, while agri and performance polymers segment registered 44.1 per cent increase of sales at Rs 169 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
